Annual Shareholders Equity
$196.99 M
+$4.09 M+2.12%
December 31, 2023
Summary
- As of February 22, 2025, TARS annual stockholders equity is $196.99 million, with the most recent change of +$4.09 million (+2.12%) on December 31, 2023.
- During the last 3 years, TARS annual shareholders equity has risen by +$31.01 million (+18.68%).
- TARS annual shareholders equity is now at all-time high.
Performance
TARS Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Shareholders Equity
$237.48 M
-$14.76 M-5.85%
September 30, 2024
Summary
- As of February 22, 2025, TARS quarterly stockholders equity is $237.48 million, with the most recent change of -$14.76 million (-5.85%) on September 30, 2024.
- Over the past year, TARS quarterly shareholders equity has increased by +$40.50 million (+20.56%).
- TARS quarterly shareholders equity is now -13.71% below its all-time high of $275.21 million, reached on March 31, 2024.
Performance
TARS Quarterly Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Shareholders Equity Formula
Shareholders Equity = Total Assets − Total Liabilities
TARS Shareholders Equity Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +2.1% | +20.6% |
| 3 y3 years | +18.7% | +20.6% |
| 5 y5 years | +10000.0% | +20.6% |
TARS Shareholders Equity Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +18.1% | -13.7% | +60.8% |
| 5 y | 5-year | at high | +3380.4% | -13.7% | +1432.0% |
| alltime | all time | at high | +3380.4% | -13.7% | +1432.0% |
Tarsus Pharmaceuticals Shareholders Equity History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $237.48 M(-5.9%) |
| Jun 2024 | - | $252.25 M(-8.3%) |
| Mar 2024 | - | $275.21 M(+39.7%) |
| Dec 2023 | $196.99 M(+2.1%) | $196.99 M(-7.8%) |
| Sep 2023 | - | $213.66 M(+44.6%) |
| Jun 2023 | - | $147.73 M(-14.8%) |
| Mar 2023 | - | $173.40 M(-10.1%) |
| Dec 2022 | $192.90 M | $192.90 M(-4.8%) |
| Sep 2022 | - | $202.63 M(-8.5%) |
| Jun 2022 | - | $221.50 M(+48.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $149.20 M(-10.5%) |
| Dec 2021 | $166.73 M(+0.5%) | $166.73 M(-6.9%) |
| Sep 2021 | - | $179.14 M(-6.9%) |
| Jun 2021 | - | $192.47 M(+5.0%) |
| Mar 2021 | - | $183.23 M(+10.4%) |
| Dec 2020 | $165.98 M(-2864.0%) | $165.98 M(-1031.0%) |
| Sep 2020 | - | -$17.83 M(-134.0%) |
| Jun 2020 | - | $52.37 M(-972.1%) |
| Dec 2019 | -$6.00 M(+343.5%) | -$6.00 M |
| Dec 2018 | -$1.35 M | - |
FAQ
- What is Tarsus Pharmaceuticals annual stockholders equity?
- What is the all time high annual shareholders equity for Tarsus Pharmaceuticals?
- What is Tarsus Pharmaceuticals annual shareholders equity year-on-year change?
- What is Tarsus Pharmaceuticals quarterly stockholders equity?
- What is the all time high quarterly shareholders equity for Tarsus Pharmaceuticals?
- What is Tarsus Pharmaceuticals quarterly shareholders equity year-on-year change?
What is Tarsus Pharmaceuticals annual stockholders equity?
The current annual shareholders equity of TARS is $196.99 M
What is the all time high annual shareholders equity for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals all-time high annual stockholders equity is $196.99 M
What is Tarsus Pharmaceuticals annual shareholders equity year-on-year change?
Over the past year, TARS annual stockholders equity has changed by +$4.09 M (+2.12%)
What is Tarsus Pharmaceuticals quarterly stockholders equity?
The current quarterly shareholders equity of TARS is $237.48 M
What is the all time high quarterly shareholders equity for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals all-time high quarterly stockholders equity is $275.21 M
What is Tarsus Pharmaceuticals quarterly shareholders equity year-on-year change?
Over the past year, TARS quarterly stockholders equity has changed by +$40.50 M (+20.56%)